Understanding Ramus Calcium Agatston: Normal vs Optimal Ranges

?What is Ramus Calcium Agatston?

The ramus calcium Agatston score measures coronary artery calcification specifically in the ramus intermedius branch of the left coronary system using non-contrast cardiac CT imaging. This segmental score is part of comprehensive coronary calcium scoring and reflects calcified plaque burden in this particular vessel. Higher Agatston scores correlate with increased atherosclerotic disease burden in this arterial segment.

!Why It Matters

Elevated ramus calcium Agatston scores may suggest accelerated atherosclerosis and can be associated with increased risk of coronary artery disease and myocardial infarction. This segmental measurement helps refine cardiovascular risk stratification beyond total coronary calcium burden, as regional calcification patterns can inform targeted preventive strategies. Serial measurements over time could indicate disease progression, though a single score represents a snapshot of current calcification status.

Reference Ranges

Lab normal ranges may vary between laboratories. Optimal and longevity targets are based on research literature and should be interpreted with your physician.

Symptoms of Imbalance

• Chest pain or angina
• Shortness of breath with exertion
• Fatigue or decreased exercise tolerance
• Heart palpitations
• Jaw or neck discomfort during physical activity

How to Improve Your Levels

• 1Maintain a heart-healthy diet low in saturated fats, trans fats, and processed foods
• 2Exercise regularly with at least 150 minutes of moderate-intensity aerobic activity weekly
• 3Manage blood pressure through lifestyle modifications and medical treatment if needed
• 4Control lipid levels through diet, exercise, and statin therapy when appropriate
• 5Avoid smoking and limit alcohol consumption
• 6Manage stress through meditation, yoga, or other relaxation techniques

When to Test

Ramus calcium Agatston scoring is typically performed as part of coronary artery calcium (CAC) screening in asymptomatic individuals aged 40–75 with intermediate cardiovascular risk, or in symptomatic patients with suspected coronary artery disease. Repeat testing may be considered every 3–5 years for risk stratification and monitoring of atherosclerotic progression.

Related Biomarkers